Abstract
Genome-wide association study of Parkinson’s disease (PD) identified common variants associated with lysosomal mechanism, including TMEM175, SCARB2, and CTSB. We investigated the association between common and rare variants across populations using cohorts from the Global Parkinson’s Genetics Program (GP2) (33,813 cases and 18,714 controls from 11 ancestries), and the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) whole genome sequencing (3,188 cases and 4,104 controls). In the European cohort, we confirmed significant associations with PD risk for all known genetic risk variants across the three genes and TMEM175 p.M393T as an independent genome-wide significant signal. Additionally, a novel independent signal, SCARB2 rs11547135, was detected. The burden analysis linked PD to SCARB2 in African American, Ashkenazi Jewish and East Asian cohorts. Single variants-based tests identified rare missense and synonymous variants in SCARB2 in several populations. Our study reinforces the association of lysosomal genetic variants with PD risk, revealing genetic heterogeneity across populations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/GP2code/TMEM175_SCARB2_CTSB_PDrisk
https://zenodo.org/records/15799534
Funding Statement
GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (MJFF). W.S. acknowledges the support of the China Scholarship Council program (Project ID: 202207040033).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Global Parkinson's Genetics Program (GP2) consortium and contributing institutions gave ethical approval for the collection and use of the human genetic data analyzed in this study. Access to de-identified GP2 Tier 2 data (release 10) was obtained through AMP PD (https://amp-pd.org) under approved data use agreements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The corresponding author has been updated from Dr. Manuela Tan to Prof. Thomas Gasser.
Data Availability
Data used in the preparation of this article were obtained from the Global Parkinson's Genetics Program (GP2; https://gp2.org). Specifically, we used Tier 2 data from GP2 release 10 (https://doi.org/10.5281/zenodo.15748014). GP2 data are available on AMP PD (https://amp-pd.org).
